MicroPhage seeks bankruptcy protection
MicroPhage will attempt to reorganize, according to documents filed Dec. 28 with the Colorado District of the U.S. Bankruptcy Court.
Founded in 2002, MicroPhage develops blood tests that identify bacterial infections. Its first product is the KeyPath MRSA/MSSA blood culture test, which identifies Staphylococcus aureus and whether it is MRSA resistant. MRSA infections do not respond to antibiotics usually prescribed to treat infections and…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!

